Long-term Outcomes After Transplantation Following Support with a Pulsatile Pediatric Ventricular Assist Device

Heart transplantation remains the most effective long-term palliation for children with end-stage heart failure. Unfortunately, this group of patients continues to have the highest waitlist mortality.1,2 With the introduction of durable ventricular assist devices (VAD) for children, there has been a reduction in this waitlist mortality.3,4 In 2012, the successful Berlin Heart EXCOR Investigational Device Exemption (IDE) trial resulted in the first Food and Drug Administration (FDA) approved pediatric ventricular assist device as a bridge to transplantation (BTT).

Source: The Journal of Heart and Lung Transplantation - October 26, 2018 Category: Transplant Surgery Authors: Aamir Jeewa, Michiaki Imamura, Charles Canter, Robert A. Niebler, Christina VanderPluym, David N. Rosenthal, James K. Kirklin, Ryan S. Cantor, Margaret Tresler, David Michael McMullan, Victor O. Morell, Mark Turrentine, Rebecca Ameduri, Khanh Nguyen, Kirk Source Type: research